Differentiation of dopamine agonists and their role in the treatment of Parkinson's disease

Journal of Neural Transmission, Supplement

Volumn , Issue 56, 1999, Pages 185-192

  Calne, Donald B ^a  

^a VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; PERGOLIDE; ANTIPARKINSON AGENT; DOPAMINE RECEPTOR;

CONFERENCE PAPER; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; AMINO ACID SEQUENCE; CHEMISTRY; MOLECULAR GENETICS; REVIEW;

AMINO ACID SEQUENCE; ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; HUMANS; MOLECULAR SEQUENCE DATA; PARKINSON DISEASE; RECEPTORS, DOPAMINE;

EID: 0032588327     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6360-3_12     Document Type: Conference Paper

References (29)

1. Calne DB (1993) Treatment of Parkinson's disease. N Engl J Med 329; 1021-1027
2. Calne DB, Teychenne PF, Claveria LE, Eastman R, Greenacre JK, Petrie A (1974a) Bromocriptinc in parkinsonism. Br Med J 4: 442-444
3. Calne DB, Teychenne PF, Leigh PN, Bamji AN, Greenacre JK (1974b) Treatment of parkinsonism with bromocriptine. Lancet 2: 1355-1366
4. Civelli O, Bunzow JR, Grandy DK, Zhou Q-Y, Van Tol HHM (1991) Molecular biology of the dopamine receptors. Eur J Pharmacol 207: 277-286
5. Corrodi H, Fuxe K, Hokfelt T, Lidbrink P, Ungerstedt U (1973) Effect of ergot drugs on central catecholamine neurons: Evidence for a stimulation of central dopamine neurons. J Pharm Pharmacol 25: 409-411
6. Cotzias GC, Van Woert MH, Schiffer LM (1967) Aromatic amino acids and modification of parkinsonism. New Engl J Med 276: 374-379
7. Ehringer H, Hornykiewicz O (1960) Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen Wien Klin Wochenschr 38: 1236-1239
8. Fluekiger E (1972) Drugs and the control of prolactin secretion. In: Boyns AR, Griffiths K (eds) Prolactin and carcinogenesis. Alpha Omega Alpha Publishing, Cardiff: 162-171
9. Fluekiger E, Briner U, Kovacs E, et al (1981) Prolactin secretion stimulation by an ergopeptine. Experientia 37: 669
10. Fluckiger E, Briner LJ, Enz A, Markstein R, Vigouret JM (1983) Dopaminergic compounds: An overview. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven Press, New York: 1-9
11. Frantz AG, Kleinberg DL (1970) Prolactin: Evidence that it is separate from growth hormone in human blood. Science 170: 745-747
12. Fuxe K, Hokfelt T (1970) Central monoaminergic systems and hypothalamic function. In: Martini L, Motta M, Fraschini F (eds) The hypothalamus. Academic Press, New York: 123-138
13. Geschwind II (1972) Introduction. In: Boyns AR, Griffiths K (eds) Prolactin and cardiogenesis. Alpha Omega Alpha Publishing, Cardiff: 1-3
14. Grondin R, Bedard PJ, Britton DR, Shiosaki K (1997) Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys. Neurology 49: 421-426
15. Hokfelt T, Fuxe K (1972) On the morphology and the neuroendocrine role of the hypothalamic catecholamine neurons. In: Knigge KM, Scott DE, Weindl A (eds) Brain-endocrine interaction. Median eminence: structure and function. Karger, Basel: 181-223
16. Hwang P, Friesen H, Hardy J, Wilansky D (1971a) Biosynthesis of human growth hormone and prolactin by normal pituitary glands and pituitary adenomas. J Clin Endocrinol 33: 1-7
17. Hwang P, Guyda H, Friesen HC (1971b) A radioimmunoassay for human prolactin. Proc Natl Acad Sci USA 68: 1902-1906
18. Johnson AM, Vigouret JM, Loew DM (1973) Central dopaminergic actions of ergotoxine alkaloids and some derivatives. Experientia 29: 763
19. Kebabian JW, Calne DB (1979) Multiple receptor mechanisms for dopamine. Nature 227: 93-96
20. Kebabian JW, Greengard P (1991) Dopamitie-sensitive adenyl cyclase: possible role in synaptic transmission. Science 174: 1346-1349
21. Lewis UJ, Singh RNP, Sinha YN, VahderLaan WP (1971) Electrophoretic evidence for human prolactin. J Clin Endocrinol 33: 153-156
22. Loewenstein JE, Mariz IK, Peake GT, Daughaday WH (1971) Prolactin bioassay by induction of N-acetyllactosamine synthetase in mouse mammary explants. J Clin Endocrinol 33: 217-224
23. Lutterbeck PM, Pryor S, Varga L, Wenner R (1971) Treatment of non-puerperal galactorrhea with an ergot alkaloid. Br Med J 3: 228-229
24. Pasteels JL (1972) Tissue culture of human hypophyses: evidence of a specific prolactin in man. In: Wolstenholme GEW, Knight J (eds) Lactogenic hormones. Churchill Livingslone, Edinburgh: 269-277
25. Pasteels JL (1973) Introduction. In: Pasteels JL, Robyn C (eds) Human prolactin. Excerpta Medica, Amsterdam: xi-xiii
26. Pasteels JL, Danguy A, Frerotte M, Ectors F (1971) Inhibition de la secretion de prolactine par I'ergocornine et la 2-Br-alpha-ergokryptine: action directe sur l'hypophyse en culture. Ann Endocrinol (Paris) 32: 188-192
27. Sibley DR, Monsma FJJ (1992) Molecular biology of dopamine receptors. TIPS 131(13): 61-69
28. Strange P (1997) Biochemical characterization of dopamine receptors. In: Neve KA, Neve RL (eds) The dopamine receptors. Humana Press, Totowa, NJ: 3-26
29. Turkington RW (1971) Measurement of prolactin activity in human serum by the induction of specific milk proteins in mammary gland in vitro. J Clin Endocrinol 33: 210-216